Literature DB >> 22864646

Novel immune signals and atherosclerosis.

Hiroshi Iwata1, Ryozo Nagai.   

Abstract

Atherosclerosis underlies coronary artery disease (CAD) and cerebrovascular disease, which are the most common forms of life-threatening cardiovascular disorders. To minimize the risk of atherosclerotic complications, primary and secondary prevention strategies seek to control risk factors. Reducing low-density lipoprotein (LDL) cholesterol through lipid-lowering drugs, such as statins, in particular yields a proportional decrease in cardiovascular disease risk. Atherosclerosis is considered to be a complex chronic inflammatory process triggered by cardiovascular risk factors which cause endothelial dysfunction and inflammatory cell infiltration within the artery wall. In this review, we summarize the current understanding of the underling molecular mechanisms of the immune signals in the development and progression of atherosclerosis. Among various molecular mechanisms, toll like receptors (TLRs) are potent proinflammatory cytokines that operate to induce inflammation play an important role in the pathogenesis of atherosclerosis. Moreover, we discuss current knowledge regarding monocyte/macrophage biology that contributes to the progression of atherosclerosis, including macrophage polarization and heterogeneity. Understanding the molecular mechanisms in conjunction with orchestration of monocyte/macrophage biology should provide a basis for novel treatment strategies to prevent the development and progression of atherosclerosis.

Entities:  

Mesh:

Year:  2012        PMID: 22864646     DOI: 10.1007/s11883-012-0267-7

Source DB:  PubMed          Journal:  Curr Atheroscler Rep        ISSN: 1523-3804            Impact factor:   5.113


  70 in total

Review 1.  The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors.

Authors:  Taro Kawai; Shizuo Akira
Journal:  Nat Immunol       Date:  2010-04-20       Impact factor: 25.606

Review 2.  The macrophage scavenger receptor at 30 years of age: current knowledge and future challenges.

Authors:  David R Greaves; Siamon Gordon
Journal:  J Lipid Res       Date:  2008-12-11       Impact factor: 5.922

3.  The time for cardiovascular inflammation reduction trials has arrived: how low to go for hsCRP?

Authors:  Paul M Ridker
Journal:  Arterioscler Thromb Vasc Biol       Date:  2008-07       Impact factor: 8.311

4.  Upregulation of VCAM-1 and ICAM-1 at atherosclerosis-prone sites on the endothelium in the ApoE-deficient mouse.

Authors:  Y Nakashima; E W Raines; A S Plump; J L Breslow; R Ross
Journal:  Arterioscler Thromb Vasc Biol       Date:  1998-05       Impact factor: 8.311

5.  Differential effects of regulatory T cells on the initiation and regression of atherosclerosis.

Authors:  A C Foks; V Frodermann; M ter Borg; K L L Habets; I Bot; Y Zhao; M van Eck; Th J C van Berkel; J Kuiper; G H M van Puijvelde
Journal:  Atherosclerosis       Date:  2011-05-05       Impact factor: 5.162

6.  Hematopoietic stem cells differentiate into vascular cells that participate in the pathogenesis of atherosclerosis.

Authors:  Masataka Sata; Akio Saiura; Atsushi Kunisato; Akihiro Tojo; Seiji Okada; Takeshi Tokuhisa; Hisamaru Hirai; Masatoshi Makuuchi; Yasunobu Hirata; Ryozo Nagai
Journal:  Nat Med       Date:  2002-04       Impact factor: 53.440

7.  Combined deficiency of ABCA1 and ABCG1 promotes foam cell accumulation and accelerates atherosclerosis in mice.

Authors:  Laurent Yvan-Charvet; Mollie Ranalletta; Nan Wang; Seongah Han; Naoki Terasaka; Rong Li; Carrie Welch; Alan R Tall
Journal:  J Clin Invest       Date:  2007-12       Impact factor: 14.808

8.  A combination of Lox-1 and Nox1 regulates TLR9-mediated foam cell formation.

Authors:  Jin-Gu Lee; Eun-Jung Lim; Dae-Weon Park; Sun-Hye Lee; Jae-Ryong Kim; Suk-Hwan Baek
Journal:  Cell Signal       Date:  2008-09-11       Impact factor: 4.315

Review 9.  Macrophage death and defective inflammation resolution in atherosclerosis.

Authors:  Ira Tabas
Journal:  Nat Rev Immunol       Date:  2009-12-04       Impact factor: 53.106

10.  Macrophage Phenotype Modulation by CXCL4 in Atherosclerosis.

Authors:  Christian A Gleissner
Journal:  Front Physiol       Date:  2012-01-13       Impact factor: 4.566

View more
  6 in total

1.  Better diet quality and decreased mortality among myocardial infarction survivors.

Authors:  Shanshan Li; Stephanie E Chiuve; Alan Flint; Jennifer K Pai; John P Forman; Frank B Hu; Walter C Willett; Kenneth J Mukamal; Eric B Rimm
Journal:  JAMA Intern Med       Date:  2013-10-28       Impact factor: 21.873

2.  L-tetrahydropalamatine inhibits tumor necrosis factor-α-induced monocyte-endothelial cell adhesion through downregulation of intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 involving suppression of nuclear factor-κ B signaling pathway.

Authors:  Bin-rui Yang; Nan Yu; Yan-hui Deng; Pui Man Hoi; Bin Yang; Guang-yu Liu; Wei-hong Cong; Simon Ming-yuen Lee
Journal:  Chin J Integr Med       Date:  2015-03-17       Impact factor: 1.978

3.  Association study to evaluate FoxO1 and FoxO3 gene in CHD in Han Chinese.

Authors:  Ying Zhao; Yanbo Yu; Xiaoli Tian; Xi Yang; Xueqi Li; Feng Jiang; Yundai Chen; Maowei Shi
Journal:  PLoS One       Date:  2014-01-28       Impact factor: 3.240

4.  Critical role of TLR2 and MyD88 for functional response of macrophages to a group IIA-secreted phospholipase A2 from snake venom.

Authors:  Elbio Leiguez; Karina Cristina Giannotti; Vanessa Moreira; Márcio Hideki Matsubara; José María Gutiérrez; Bruno Lomonte; Juan Pablo Rodríguez; Jesús Balsinde; Catarina Teixeira
Journal:  PLoS One       Date:  2014-04-09       Impact factor: 3.240

5.  Association between Toll-like receptor 4 Asp299Gly polymorphism and coronary heart disease susceptibility.

Authors:  B W Wu; J Zhu; H M Shi; B Jin; Z C Wen
Journal:  Braz J Med Biol Res       Date:  2017-08-07       Impact factor: 2.590

6.  ERCC5, HES6 and RORA are potential diagnostic markers of coronary artery disease.

Authors:  Zhifeng Bai; Yuanyuan Luo; Linyun Tian
Journal:  FEBS Open Bio       Date:  2022-08-07       Impact factor: 2.792

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.